Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

Summary

The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia. This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.

Timeline

Start

2013-10

Primary completion

2014-04

Completion

2014-04

Drugs

Indications